Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2004 | 31 | 2 |
Tytuł artykułu

Niealkoholowa choroba stluszczeniowa watroby jako nastepstwo ogolnoustrojowych zaburzen metabolicznych

Opis fizyczny
  • Instytut Zywnosci i Zywienia, Warszawa
  • 1. Christoffersen E, Nielsen K.: Histologic changes in human liver biopsies from chronic alcoholics. Acta Pathol. Microbiol. Scand. (A), 1972, 80, 557, 21.
  • 2. Lieber C. S., Jones D. E, Decarli L. M.: Effects of prolonged ethanol intake: production of fatty liver despite adequate diets. J. Clin. Invest. 1965, 44, 1009.
  • 3. Sherlock S., Dooley J.: Nutritional and Metabolic Liver Diseases. In: Diseases of the liver and biliary system. Ed: S. Sherlock, J. Dooley. Oxford, Blackwell Eublishing, 2002, 426.
  • 4. Ludwig J., Viggano T., McGill D. B., Ott B. J.: Nonalcoholic steatohepatitis Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc., 1980, 55, 434-438.
  • 5. Allard J.P.: Other disease associations with non-alcoholic fatty liver disease (NAFLD). Best Pract. Res. Clin. Gastroenterol., 2002, 16, 783-795.
  • 6. Schaffner F.: Nonalcoholic fatty liver disease. In: Progres in liver disease. Ed: F. Schaffner. London, Grune Stratton, 1986, 283.
  • 7. Sanyal A.J., Campbell-Sargent C., Mirshahi F., et al.: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology, 2001, 120, 1183-92.
  • 8. Boden G.: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes, 1997, 46, 3-10.
  • 9. Fan C.Y., Pan J., Usuda N, et al.: Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acylCoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J. Biol. Chem., 1998, 19, 273, 15639-15645.
  • 10. Caldwell S. H., Swerdlow R. H., Khan E. M., et al.: Mitochondrial abnormalities in non-alcoholic steatohepatitis. J. Hepatol., 1999, 31, 430-434.
  • 11. Cortez-Pinto H., Chatham J., Chacko V. P., et al: Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. J. Am. Med. Assoc., 1999, 3, 282, 1659-1664.
  • 12. Boden G.: Interaction between free fatty acids and glucose metabolism. Curr. Opin. Clin. Nutr. Metab. Care, 2002, 5, 545-549.
  • 13. Hotamisligil G. S., Peraldi P., Budavari A., et al.: IRS-l-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science, 1996, 2, 271, 665-668.
  • 14. Tacikowski T., Milewski B., Dzieniszewski J., Walewska-Zielecka B.: Stluszczenie wątroby oceniane badaniem histopatologicznym u osób z hiperlipoproteinemią. Wiad. Lek., 1994, 47, 19-20, 731-737.
  • 15. Tacikowski T., Dzieniszewski J.: Prevalence of Non-Alcoholic Hepatic Steatosis Depending on Overweight Degree in Individuals with Hyperlipoprote- inaemia. Adv. Clin. Exp. Med., 2001,10, 139-143.
  • 16. Liu T. Y, Lu S. N., Su W. P., et al.: Prediction of fatty liver from serum triglyceride levels and body weight indexes. Kao Hsiung I Hsueh Ko Hsueh Tsa Chih, 1990, 6, 289-294.
  • 17. Tacikowski T., Dzieniszewski J., Rakoczy A., Tacikowska M.: Hipertrójglicerydemia jako niezależny od otyłości czynnik ryzyka rozwoju stłuszczenia wątroby u osób z hiperlipoproteinemią. Gastroenterol. Pol., 2001, 8, 143-147.
  • 18. Assy N., Kaita K., Mymin D,. et al.: Fatty infiltration of liver in hyperlipidemic patients. Dig. Dis. Sei., 2000, 45, 1929-1934.
  • 19. Heymsfield S. B., Greenberg A. S., Fujioka K., et al.: Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. J. Am. Med. Assoc., 1999, 282,1568-75.
  • 20. Cinti S., de Matteis R., Ceresi E., et al.: Leptin in the human stomach. Gut, 2001, 49, 155.
  • 21. Schwartz M. W., Woods S. C., Porte D., et al.: Central nervous system control of food intake. Nature 2000 404. 661-71.
  • 22. Wilding J. P.: Neuropeptides and appetite control. Diabet. Med., 2002., 19, 619-27.
  • 23. Song Y., Golling G., Thacker T.L., Cone R. D. : Agouti-related protein (AGRP) is conserved and regulated by metabolic state in the zebrafish, Danio rerio. Endocrine, 2003, 22, 257-65.
  • 24. Marchesini G., Brizi M., Bianchi G., et al.: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes, 2001, 50, 1844-1850.
  • 25. Pagano G., Pacini G., Musso G., et al.: Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologie association. Hepatology, 2002, 35, 367-372.
  • 26. Chitturi S., Abeygunasekera S., Farrell G. C., et al.: NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology, 2002, 35, 373-379.
  • 27. Diehl A. M.: Nonalcoholic steatohepatitis. Semin. Liver Dis., 1999, 19, 221-229.
  • 28. Clark J. M., Brancati F. L., Diehl A. M. E.: Nonalcoholic fatty liver diseases; the most common cause of abnormal liver enzymesin the U. S. population. Gastroenterology, 2001,120, A-65.
  • 29. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med., 2002, 346, 1221-1231.
  • 30. Luyckx F.H., Desaive C., Thiry A., et al.: Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int. J. Obes. Relat. Metab. Disord., 1998, 22, 222-226.
  • 31. Harris M. I., Flegal K. M., Cowie C. C., et al.: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U. S. adults. The Third National Health and Nutrition Examination Survey,1988-1994. Diabetes Care, 1998, 21, 518-524.
  • 32. Program Pol-Monica. Warszawa. Kompleksowa ocena stanu zdrowia ludności Warszawy w roku 1993 i jego zmian w latach 1984-1993. Red: S. Rywik. Część V Instytut Kardiologii. Warszawa 1995.
  • 33. Tacikowski T., Milewski B., Dzieniszewski J., i in.: Stłuszczenie wątroby oceniane badaniem ultrasonograficznym u osób z hiperlipoproteinemią. Wiad. Lek., 1994, 47, 19-20, 726-730.
  • 34. Matsuura K., Tobe K., Tsuji T.: [Fatty liver and obesity in university students]. Nippon- Shokakibyo- Gakkai-Zasshi., 1995, 92, 1743-1751.
  • 35. Osono Y., Nakajiama K., Hata Y.: Hypertriglyceridemia and fatty liver: clinical diagnosis of fatty liver and lipoprotein profiles in hypertriglyceridemicpatients with fatty liver. J. Atheros. and Throm.,1995, 2, Suppl. S 47.
  • 36. Lu S. N., Wang L. Y., Chang W. Y., et al.: Abdominal sonographic screening in a single community. Kao Hsiung I Hsueh Ko Hsueh Tsa Chih., 1990,6, 643-646.
  • 37. Doherty J. F., Adam E. J., Griffin G. E., Golden M. H.: Ultrasonographic assessment of the extent of hepatic steatosis in severe malnutrition. Arch. Dis. Child., 1992, 67, 1348-1352.
  • 38. Suzuki K., Hayashi N., Sasaki Y., et al.: Evaluation of structural change in diffuse liver disease with frequency domain analysis of ultrasound. Hepatology,1993, 17, 1041-1046.
  • 39. Yamasaki H., Tanemura M., Morimoto Y., et al.: [Study of postgastrectomy fatty liver].Nippon Geka Gakkai Zasshi,1992, 93, 1384-1389.
  • 40. Saadeh S., Younossi Z. M., Remer E. M., et al.: The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology, 2002, 123, 745-750.
  • 41. Brallon A., Capron J. P, Herve M. A., et al.: Liver in obesity. Gut, 1985, 26, 133-139.
  • 42. Evans C. D., Oien K. A., MacSween R. N., Mills P. R.: Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? J. Clin. Pathol., 2002, 55, 689-692.
  • 43. Dixon J. B., Bhathal P. S., O'Brien P. E.: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology, 2001, 121, 91-100.
  • 44. Bellentani S., Saccoccio G., Masutti F., et al.: Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med., 2000, 18, 132, 112-117.
  • 45. Marrero J. A., Fontana R. J., Su G. L., et al.: NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology, 2002, 36, 1349-1354.
  • 46. Andersen T., Gluud C., Franzmann M. B., Christoffersen P.: Hepatic effects of dietary weight loss in morbidly obese subjects. J. Hepatol., 1991, 12,: 224-229.
  • 47. Basaranoglu M., Acbay O., Sonsuz A.: A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J. Hepatol., 1999, 31, 384.
  • 48. Lavine J. E.: Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J. Pediatr., 2000, 136, 734-738.
  • 49. Marchesini G., Brizi M., Bianchi G., et al.: Metformin in non-alcoholic steatohepatitis. Lancet, 2001, 358, 893-894.
  • 50. Laurin J., Lindor K. D., Crippin J. S., et al.: Ursodeoxycholic acid or Clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology, 1996, 23, 1464-1467.
  • 51. Caldwell S. H., Hespenheide E. E., Redick J. A., et al.: A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am. J. Gastroenterol., 2001, 96, 519-525.
  • 52. Contos M. J., Cales W., Sterling R. K., et al.: Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl., 2001, 7, 363-733.
  • 53. Charlton M., Kasparova P., Weston S., et al.: Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl., 2001, 7, 608-614.
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.